The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.

[1]  R. Vink,et al.  Treatment with a Substance P Receptor Antagonist Is Neuroprotective in the Intrastriatal 6-Hydroxydopamine Model of Early Parkinson's Disease , 2012, PloS one.

[2]  Jim Manavis,et al.  Automatic Nonsubjective Estimation of Antigen Content Visualized by Immunohistochemistry Using Color Deconvolution , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  M. Fälth,et al.  l-DOPA-induced Dyskinesia is Associated with Regional Increase of Striatal Dynorphin Peptides as Elucidated by Imaging Mass Spectrometry , 2011, Molecular & Cellular Proteomics.

[4]  R. Vink,et al.  Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System Injury , 2010, Molecules.

[5]  R. Vink,et al.  A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death , 2010, Neuroscience Letters.

[6]  R. Watts,et al.  Striatal Overexpression of ΔFosB Reproduces Chronic Levodopa-Induced Involuntary Movements , 2010, The Journal of Neuroscience.

[7]  M. Cyr,et al.  Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat , 2010, Neurobiology of Disease.

[8]  C. Barnum,et al.  The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats , 2009, Synapse.

[9]  C. Barnum,et al.  Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: Role for interleukin-1β , 2008, Neuroscience.

[10]  M. Jahanshahi,et al.  Quality of life in Parkinson's disease: The relative importance of the symptoms , 2008, Movement disorders : official journal of the Movement Disorder Society.

[11]  K. Bost,et al.  Neurogenic Exacerbation of Microglial and Astrocyte Responses to Neisseria meningitidis and Borrelia burgdorferi1 , 2008, The Journal of Immunology.

[12]  M. Cenci,et al.  Advances in understanding l-DOPA-induced dyskinesia , 2007, Current Opinion in Neurobiology.

[13]  W. Danysz,et al.  Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model , 2007, Behavioural Brain Research.

[14]  J. Nyengaard,et al.  Endothelial Proliferation and Increased Blood–Brain Barrier Permeability in the Basal Ganglia in a Rat Model of 3,4-Dihydroxyphenyl-l-Alanine-Induced Dyskinesia , 2006, The Journal of Neuroscience.

[15]  L. Descarries,et al.  Immunocytochemical evidence for the existence of substance P receptor (NK1) in serotonin neurons of rat and mouse dorsal raphe nucleus , 2006, The European journal of neuroscience.

[16]  F. Fadda,et al.  Role of striatal l‐DOPA in the production of dyskinesia in 6‐hydroxydopamine lesioned rats , 2006, Journal of neurochemistry.

[17]  P. Walker,et al.  Intranigral antagonism of neurokinin 1 and 3 receptors reduces intrastriatal dopamine D1 receptor-stimulated locomotion in the rat , 2004, Brain Research.

[18]  J. Obeso,et al.  The origin of motor fluctuations in Parkinson’s disease , 2004, Neurology.

[19]  A. Björklund,et al.  l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function , 2002, Neurobiology of Disease.

[20]  N. Wierup,et al.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease , 2002, The European journal of neuroscience.

[21]  M. Andersson,et al.  Persistent changes in striatal gene expression induced by long‐term l‐DOPA treatment in a rat model of Parkinson's disease , 2001, The European journal of neuroscience.

[22]  D. Sutoo,et al.  Quantitative imaging of substance P in the human brain using a brain mapping analyzer , 1999, Neuroscience Research.

[23]  M. Andersson,et al.  Striatal fosB Expression Is Causally Linked with l -DOPA-Induced Abnormal Involuntary Movements and the Associated Upregulation of Striatal Prodynorphin mRNA in a Rat Model of Parkinson's Disease , 1999, Neurobiology of Disease.

[24]  A. Björklund,et al.  L‐DOPA‐induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin‐ and glutamic acid decarboxylase mRNA , 1998, The European journal of neuroscience.

[25]  J. Labandeira-Garcia,et al.  An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. , 1997, Brain research. Brain research protocols.

[26]  A. Lees,et al.  Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[27]  E. Nestler,et al.  Chronic Alterations in Dopaminergic Neurotransmission Produce a Persistent Elevation of ΔFosB‐like Protein(s) in both the Rodent and Primate Striatum , 1996, The European journal of neuroscience.

[28]  A. Björklund,et al.  Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  C. Gerfen,et al.  Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats , 1991, Brain Research.

[30]  Y. Agid,et al.  Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains , 1983, Brain Research.

[31]  P. Jenner.  Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities , 2008, Movement disorders : official journal of the Movement Disorder Society.

[32]  B. Pike,et al.  The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. , 1994, Journal of neurotrauma.

[33]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .